Research programme: neurological and cancer therapeutics - BIOALVO

Drug Profile

Research programme: neurological and cancer therapeutics - BIOALVO

Alternative Names: BLV 0801; IDO inhibitors

Latest Information Update: 01 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIOALVO
  • Class
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Neurological disorders

Most Recent Events

  • 01 Feb 2011 Preclinical development is ongoing in Portugal
  • 26 Feb 2007 Preclinical development is ongoing
  • 29 Aug 2005 Potential therapeutics from this programme will be available for licensing (http://www.bioalvo.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top